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Objective: Current data supporting the effect of anticoagulation drug
use on aneurysm sealing and the durability of endovascular abdominal aneu-
rysm repair (EVAR) are conﬂicting. This study assessed the safety of chronic
anticoagulation therapy after EVAR.
Methods: Records of 1409 consecutive patients having elective
EVAR during 1997-2011 who were prospectively followed were reviewed.
Survival, reintervention, conversion, and endoleak rates were analyzed in pa-
tients with and without chronic anticoagulants. Cox proportional hazards
models were used to estimate the effect of anticoagulation therapy on
outcomes.
Results: One-hundred and three (7.3%) patients were on chronic
anticoagulation drugs (80 on vitamin K antagonists) at the time of
EVAR. An additional 46 patients started on anticoagulants after repair
were identiﬁed. Patients on chronic anticoagulation therapy at repair
(mean age 73.6 years; 91 males) had more frequent cardiac disease
(74.8% vs 44.2%; P < .00001), but no other differences in demographic
and major baseline comorbidities with respect to the others. At baseline,
mean abdominal aortic aneurysm (AAA) diameter was 56.43 mm vs
54.65 mm (P = .076) and aortic neck length 26.54 mm vs 25.21 mm (P
= .26) in patients with and without anticoagulants, respectively. At 5 years,
freedom from endoleak rates were 55.5% vs 69.9% (P < .0001), and
freedom from reintervention/conversion rates were 69.4% vs 82.4% (P <
.0001) in patients with (including those with delayed drug use) and without
chronic anticoagulants, respectively. Controlling for covariates with the Cox
regression method, at a mean follow-up of 64.3 6 45.2 months after
EVAR, use of anticoagulation drugs was independently associated with an
increased risk of endoleak (odds ratio, OR 1.6; 95% conﬁdence interval,
CI: 1.23-2.07; P < .0001) and reintervention or late conversion rates
(OR 1.8; 95% CI: 1.31-2.48; P < .0001).
Conclusions: The safety of anticoagulation therapy after EVAR is
debatable. Chronic anticoagulation drug use risks exposure to a poor
long-term outcome. A critical and balanced decision-making approachshould be applied to patients with AAA and cardiac disease who may require
prolonged anticoagulation treatment.
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Objectives: Supervised exercise training (SET) is recommended for
patients with intermittent claudication (IC). The optimal exercise pro-
gramme has not been identiﬁed, and the potential adverse effects of exercise
on these patients warrant consideration. Calpain proteases have been linked
with tissue atrophy following ischaemiaereperfusion injury. High calpain
activity may therefore cause muscle wasting in claudicants undergoing
SET, and skeletal muscle mass (SMM) is integral to healthy ageing. This
study assesses the impact of (1) treadmill-based SET alone; and (2) tread-
mill-based SET combined with resistance training on pain-free walking dis-
tance (PFWD), SMM, and calpain activity.
Methods: Thirty-ﬁve patients with IC were randomised to 12 weeks
of treadmill only SET (group A), or combined treadmill and lower-limb
resistance SET (group B). PFWD via a 6-minute walking test, SMM via
dual energy X-ray absorptiometry, and calpain activity via biopsies of
gastrocnemius muscles were analysed.
Results: Intention-to-treat analyses revealed PFWD improved within
group A (160 m to 204 m, P = .03), but not group B (181 m to 188 m, P =
.82). There was no between group difference (P = .42). Calpain activity
increased within group A (1.62  105 ﬂuorescent units [FU] to 2.21 
105 FU, P = .05), but not group B. There was no between group difference
(P = .09). SMM decreased within group A (250 g, P = .11) and increased
in group B (210 g, P = .38) (P = .10 between groups). Similar trends were
evident for per protocol analyses, but, additionally, change in SMM was
signiﬁcantly different between groups (P = .04).
Conclusions: Neither exercise regimen was superior in terms of
walking performance. Further work is required to investigate the impact
of the calpain system on SMM in claudicants undertaking SET.
